ArticleBMJ open2022

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.

Tobias Menne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.